Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 18;17(4):e82490.
doi: 10.7759/cureus.82490. eCollection 2025 Apr.

Drug-Induced Leukocytoclastic Vasculitis From an Unreported Source: Daptomycin

Affiliations
Case Reports

Drug-Induced Leukocytoclastic Vasculitis From an Unreported Source: Daptomycin

Jennifer K Priessnitz et al. Cureus. .

Abstract

Leukocytoclastic vasculitis (LCV) is a rare small-vessel vasculitis caused by immune-complex-mediated deposition on endothelial cells of dermal capillaries. Common triggers include medications, infections, autoimmune disorders, and malignancies. We present a case of a 58-year-old male who developed daptomycin-induced LCV after being treated for Methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. The patient experienced painful palpable purpura on his lower extremities, which was diagnosed as LCV by skin biopsy. At the time of the biopsy, warfarin and daptomycin were discontinued, and the patient was transitioned to heparin and ceftaroline. MRSA-induced LCV was ruled out, due to negative blood cultures and adequate source control of his infection at the time of development of the skin lesions. Warfarin-induced skin necrosis (WISN) was ruled out based on histopathological findings. This case is clinically significant as it represents the first reported case of LCV associated with daptomycin use. It underscores the importance of considering the patient's history, clinical presentation, and histopathological findings to ensure prompt recognition and management of this rare drug reaction, allowing for the resolution of LCV.

Keywords: antibiotic adverse effects; cutaneous drug reaction; daptomycin adverse reaction; drug-induced vasculitis; histopathology of vasculitis; immune complex-mediated vasculitis; leukocytoclastic vasculitis (lcv); mrsa endocarditis; small vessel vasculitis.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Right lower extremity painful, necrotic appearing purpura with surrounding erythema.
Figure 2
Figure 2. Erythematous macule with palpable purpura on the right lower extremity.
Figure 3
Figure 3. Biopsy of the right lower extremity demonstrating LCV.
The black circles demonstrate vessels with inflammation marked by fibrin deposition and neutrophil invasion. The green bracket highlights the area of neutrophils (polymorphonuclear cells) and fragmentations of neutrophils (leukocytoclasia). Blue arrows mark eosinophilic regions representing fibrin deposition on vessels.
Figure 4
Figure 4. Patient’s right lower extremity at the one-month follow-up visit after discontinuation of daptomycin revealing resolution of purpuric lesions, with post-inflammatory changes of dyspigmentation and crusted re-epithelializing tissue being present.
Figure 5
Figure 5. Timeline of the patient's clinical events.

Similar articles

References

    1. Dermatologic aspects of systemic vasculitis. Younger DS, Carlson A. Neurol Clin. 2019;37:465–473. - PubMed
    1. Baigrie D, Crane JS. StatPearls. Treasure Island, FL: StatPearls Publishing; 2023. Leukocytoclastic vasculitis. - PubMed
    1. A review of primary vasculitis mimickers based on the Chapel Hill Consensus Classification. Zarka F, Veillette C, Makhzoum JP. Int J Rheumatol. 2020;2020:8392542. - PMC - PubMed
    1. Coumarin-induced skin necrosis. Bauer KA. Arch Dermatol. 1993;129:766–768. - PubMed
    1. Levetiracetam-induced leukocytoclastic vasculitis. Gupta M. Indian J Pharmacol. 2017;49:124–126. - PMC - PubMed

Publication types

LinkOut - more resources